Aktuellt
SENASTE
Redeye provides its comments on Optomed’s Q3 2022 report. Revenues came in at EUR3.7m, 10.7% higher than the same period last year. There are still uncertainties in the Chinese market, but we are positive that Optomed performs well in other markets. We make slight changes in our model for full-year 22 and our WACC due to a new internal policy which renders a new base case from EUR9.0 to EUR8.5.
LÄS MER
